BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for eleven clinical indications. The company has a development and licensing agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase (XIAFLEX™). XIAFLEX was approved by the U.S. Food and Drug Administration (FDA) in February 2010 for the treatment of Dupuytren’s contracture in adults with a palpable cord in the palm. Two other promising lead indications for XIAFLEX include Peyronie's Disease and frozen shoulder (adhesive capsulitis).

Pfizer, Inc. is responsible for marketing XIAFLEX for Dupuytren's contracture and Peyronie's Disease in Europe and other territories.